NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read ...

Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an "Outperform" recommendation to the company's shares. This bullish stance reflects the company's path to ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Precipio is a microcap specialty cancer diagnostics company offering both molecular assay kits and pathology services. Precipio currently has "going concern" language in their financial audit due to ...

Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note that the conference is ...

NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the ...

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ...

Precipio, Inc., a specialty cancer diagnostics company, announced a significant agreement with its largest warrant holder, revising the exercise structure of existing warrants. Under the new terms, ...

Precipio Inc. (NASDAQ:PRPO) shares surged 140% Monday after the company successfully launched its COVID-19 rapid antibody test that tests for both IgG & IgM antibodies. Testing for antibodies will let ...

Precipio Inc. Annual stock financials by MarketWatch. View the latest PRPO financial statements, income statements and financial ratios.